A new approach to facilitate diagnosis of nonalcoholic fatty liver disease through a galactose single point method in rats with fatty liver

Digestive and Liver Disease

Volumn 45, Issue 2, 2013, Pages 134-141

  Lee, Jr Ting ^a   Pao, Li Heng ^a,b   Lee, Meei Shyuan ^a   Liao, Jiunn Wang ^c   Shih, Chi Min ^d   Hsiong, Cheng Huei ^a   Yin, Fon Yi ^a   Shih, Tung Yuan ^a   Hu, Oliver Yoa Pu ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRANSWORLD UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Assessing liver function; Choline deficient diet; Galactose single point method (GSP); Nonalcoholic fatty liver disease (NAFLD)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GALACTOSE; SILYMARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; GALACTOSE SINGLE POINT; LIVER INJURY; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SENSITIVITY AND SPECIFICITY;

ANIMALS; FATTY LIVER; GALACTOSE; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY;

EID: 84872419893     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.08.019     Document Type: Article

References (48)

1. Fallo F., Dalla Pozza A., Sonino N., et al. Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. Journal of Hypertension 2008, 26:2191-2197.
2. Bjornsson E., Angulo P. Non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology 2007, 42:1023-1030.
3. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:S99-S112.
4. Luyckx F.H., Desaive C., Thiry A., et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. International Journal of Obesity and Related Metabolic Disorders 1998, 22:222-226.
5. Knobler H., Schattner A., Zhornicki T., et al. Fatty liver-an additional and treatable feature of the insulin resistance syndrome. The Quarterly Journal of Medicine 1999, 92:73-79.
6. Falck-Ytter Y., Younossi Z.M., Marchesini G., et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Seminars in Liver Disease 2001, 21:17-26.
7. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
8. Bacon B.R., Farahvash M.J., Janney C.G., et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107:1103-1109.
9. Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121:91-100.
10. Ratziu V., Giral P., Charlotte F., et al. Liver fibrosis in overweight patients. Gastroenterology 2000, 118:1117-1123.
11. Raszeja-Wyszomirska J., Miezynska-Kurtycz J., Marlicz W., et al. Non invasive markers of non-alcoholic steatohepatitis. Polski Merkuriusz Lekarski 2008, 25:166-170. [in Polish with English abstract].
12. Sakka S.G. Assessing liver function. Current Opinion in Critical Care 2007, 13:207-214.
13. Hu O.Y., Tang H.S., Chang C.L. The influence of chronic lobular hepatitis on pharmacokinetics of cefoperazone-a novel galactose single-point method as a measure of residual liver function. Biopharmaceutics and Drug Disposition 1994, 15:563-576.
14. Hu O.Y., Tang H.S., Chang C.L. Novel galactose single point method as a measure of residual liver function: example of cefoperazone kinetics in patients with liver cirrhosis. Journal of Clinical Pharmacology 1995, 35:250-258.
15. Hu O.Y., Tang H.S., Sheeng T.Y., et al. Pharmacokinetics of promazine in patients with hepatic cirrhosis-correlation with a novel galactose single point method. Journal of Pharmaceutical Sciences 1995, 84:111-114.
16. Tang H.S., Hu O.Y. Assessment of liver function using a novel galactose single point method. Digestion 1992, 52:222-231.
17. Young T.H., Tang H.S., Chao Y.C., et al. Quantitative rat liver function test by galactose single point method. Laboratory Animals 2008, 42:495-504.
18. Young T.H., Tang H.S., Lee H.S., et al. Effects of hyperglycemia on quantitative liver functions by the galactose load test in diabetic rats. Metabolism: Clinical and Experimental 2007, 56:1265-1269.
19. Food and Drug Administration Guidance for industry pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling 2003, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072123.pdf.
20. Cheng H.C., Yang C.M., Shiao M.S. Zonation of cholesterol and glycerolipid synthesis in regenerating rat livers. Hepatology 1993, 17:280-286.
21. Sherlock S., Dooley J. Disease of the liver and biliary system. Assessment of liver function 2002, 19-35. Blackwell Scientific, Oxford. 11th ed. S. Sherlock, J. Dooley (Eds.).
22. Weltman M.D., Farrell G.C., Hall P., et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27:128-133.
23. Weltman M.D., Farrell G.C., Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996, 111:1645-1653.
24. Serviddio G., Bellanti F., Giudetti A.M., et al. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. Journal of Pharmacology and Experimental Therapeutics 2010, 332:922-932.
25. Luper S. A review of plants used in the treatment of liver disease. Part 1. Alternative Medicine Review 1998, 3:410-421.
26. Krecman V., Skottova N., Walterova D., et al. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Medica 1998, 64:138-142.
27. Boigk G., Stroedter L., Herbst H., et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997, 26:643-649.
28. Mourelle M., Muriel P., Favari L., et al. Prevention of CCL4-induced liver cirrhosis by silymarin. Fundamental and Clinical Pharmacology 1989, 3:183-191.
29. Jia J.D., Bauer M., Cho J.J., et al. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. Journal of Hepatology 2001, 35:392-398.
30. Murray M., Zaluzny L., Dannan G.A., et al. Altered regulation of cytochrome P-450 enzymes in choline-deficient cirrhotic male rat liver: impaired regulation and activity of the male-specific androst-4-ene-3,17-dione 16 alpha-hydroxylase, cytochrome P-450UT-A, in hepatic cirrhosis. Molecular Pharmacology 1987, 31:117-121.
31. Oliveira C.P., da Costa Gayotto L.C., Tatai C., et al. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet. Journal of Cellular and Molecular Medicine 2002, 6:399-406.
32. George J., Pera N., Phung N., et al. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. Journal of Hepatology 2003, 39:756-764.
33. Hironaka K., Sakaida I., Uchida K., et al. Correlation between stellate cell activation and serum fibrosis markers in choline-deficient l-amino acid-defined diet-induced rat liver fibrosis. Digestive Diseases and Sciences 2000, 45:1935-1943.
34. Nakano M. Morphogenesis of septa in hepatic fibrosis induced by choline deficiency in rats. Correlation between ito cells, pericellular fibrosis, and septa. Acta Pathologica Japonica 1986, 36:1643-1652.
35. Henry R.J., Chiamori N., Golub O.J., et al. Revised spectrophotometric methods for the determination of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, and lactic acid dehydrogenase. American Journal of Clinical Pathology 1960, 34:381-398.
36. Kleiner D.E., Brunt E.M., Natta M.V., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
37. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. Journal of Biological Chemistry 1957, 226:497-509.
38. Miyazawa T., Suzuki T., Fujimoto K., et al. Chemiluminescent simultaneous determination of phosphatidylcholine hydroperoxide and phosphatidylethanolamine hydroperoxide in the liver and brain of the rat. Journal of Lipid Research 1992, 33:1051-1059.
39. Takahashi K., Uchiyama H., Yanagisawa S., et al. The logistic regression and ROC analysis of group-based screening for predicting diabetes incidence in four years. Kobe Journal of Medical Sciences 2006, 52:171-180.
40. Tahan V., Atug O., Akin H., et al. Melatonin ameliorates methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in rats. Journal of Pineal Research 2009, 46:401-407.
41. Koca S.S., Bahcecioglu I.H., Poyrazoglu O.K., et al. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation 2008, 31:91-98.
42. Fujita K., Nozaki Y., Wada K., et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut 2008, 57:1583-1591.
43. Lucena M.I., Andrade R.J., de la Cruz J.P., et al. Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. International Journal of Clinical Pharmacology and Therapeutics 2002, 40:2-8.
44. Teodoro J.S., Rolo A.P., Duarte F.V., et al. Differential alterations in mitochondrial function induced by a choline-deficient diet: understanding fatty liver disease progression. Mitochondrion 2008, 8:367-376.
45. Liang C.T.C.M., Hong C.C., Huang K.J. Establishing the blood chemistry reference values for SPF rats and mice. Journal of Chinese Society of Veterinary Science 1999, 25:55-68. [in Chinese with English abstract].
46. Kaplan M.M. Alkaline phosphatase. Gastroenterology 1972, 62:452-468.
47. Reichling J.J., Kaplan M.M. Clinical use of serum enzymes in liver disease. Digestive Diseases and Sciences 1988, 33:1601-1614.
48. Balistreri W.F., A-Kader H.H., Setchell K.D., Gremse D., Ryckman F.C., Schroeder T.J. New methods for assessing liver function in infants and children. Annals of Clinical and Laboratory Science 1992, 22:162-174.